|By PR Newswire||
|August 4, 2014 12:06 PM EDT||
THE WOODLANDS, Texas, Aug. 4, 2014 /PRNewswire/ -- The Berlin Heart Group announced today that they have completed enrollment in their Post Approval Study, the only condition of the "Humanitarian Device Exemption" (HDE) approval that Berlin Heart received for the EXCOR® Pediatric Ventricular Assist Device (VAD) on December 16th, 2011.
The Berlin Heart EXCOR® Pediatric VAD is a mechanical cardiac support system for critically ill pediatric patients suffering from severe heart failure. The system is designed to support pediatric patients of all age groups, from newborns to teenagers, and is intended to bridge patients awaiting heart transplantation from days to several months, until a donor heart becomes available. The Berlin Heart EXCOR® Pediatric VAD, which is also approved for use in Europe and Canada, is the only Ventricular Assist Device that is designed specifically for the pediatric population to be approved in the United States.
The purpose of the Post Approval Study for the EXCOR® Pediatric VAD was to evaluate whether safety and outcomes of the device in the commercial setting were comparable to the safety and outcomes of the device in the IDE study. The "all-comers" prospective study enrolled 39 subjects who were implanted with the device per the approved labeling. Of the 39 subjects enrolled, 34 have reached an endpoint to date. As soon as the remaining subjects reach an endpoint, the study data will be analyzed and presented to the FDA.
Bob Kroslowitz, President and CEO of Berlin Heart's North American operations, said: "We are extremely pleased that we have, with the continued support of our implanting sites, been able to satisfy the final requirement of the EXCOR Pediatric approval in a very short period of time." "As the EXCOR® Pediatric had extensive use prior to the HDE approval (available to all North American sites who requested the device under compassionate use regulations), we are confident that the results of the Post Approval Study will be consistent with the IDE Study, and in some areas will trend more favorably."
About Berlin Heart
Berlin Heart GmbH is the only company worldwide that develops, produces, and distributes implantable and external ventricular assist devices (VADs) for patients of every age and body size. The company offers pumps, cannulas, and external components for internal and external use to stabilize cardiac activity in acutely ill patients. Its products are market leaders in their respective segments in Germany and in Europe. The company also manufactures the implantable left ventricular assist device INCOR®, which has been designed for long-term application in adult patients. INCOR® is not FDA-approved, but widely used in Europe. Berlin Heart Inc., the company's US subsidiary, was founded in 2005 to support the North American centers. Further product information is available from the company website: www.berlinheart.com.
Berlin Heart Inc.
200 Valleywood, Suite B100
The Woodlands, TX 77380
SOURCE Berlin Heart Inc
Sep. 30, 2016 10:45 PM EDT Reads: 482
Sep. 30, 2016 10:45 PM EDT Reads: 1,533
Sep. 30, 2016 10:00 PM EDT Reads: 1,255
Sep. 30, 2016 09:45 PM EDT Reads: 2,842
Sep. 30, 2016 09:30 PM EDT Reads: 4,118
Sep. 30, 2016 09:30 PM EDT Reads: 5,427
Sep. 30, 2016 09:00 PM EDT Reads: 2,828
Sep. 30, 2016 09:00 PM EDT Reads: 4,048
Sep. 30, 2016 08:45 PM EDT Reads: 486
Sep. 30, 2016 08:30 PM EDT Reads: 473
Sep. 30, 2016 08:30 PM EDT Reads: 3,197
Sep. 30, 2016 08:15 PM EDT Reads: 747
Sep. 30, 2016 08:00 PM EDT Reads: 1,564
Sep. 30, 2016 07:30 PM EDT Reads: 567
Sep. 30, 2016 07:15 PM EDT Reads: 483